CNBT
APLS

Cornerstone National Bank & Trust’s Apellis Pharmaceuticals APLS Stock Holding History

Cornerstone National Bank & Trust’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,000
Closed -$452K – 61
2022
Q2 		$452K Hold
10,000
– – 0.23% 53
2022
Q1 		$508K Hold
10,000
– – 0.22% 54
2021
Q4 		$473K Hold
10,000
– – 0.21% 55
2021
Q3 		$330K Buy
+10,000
New +$562K 0.15% 60

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Cornerstone National Bank & Trust's APLS Position: Q3 2022 in Review

Cornerstone National Bank & Trust sold out of Apellis Pharmaceuticals (APLS) in Q3 2022, closing a stake of 10,000 shares — an estimated $452K sold.

Cornerstone National Bank & Trust first reported a position in APLS in Q3 2021 and held it in 4 quarters. The position peaked at $508K in Q1 2022. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

  • Cornerstone National Bank & Trust reported no remaining Apellis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cornerstone National Bank & Trust sold 10,000 Apellis Pharmaceuticals shares in Q3 2022, an estimated $452K.
  • Cornerstone National Bank & Trust first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Cornerstone National Bank & Trust's Apellis Pharmaceuticals position peaked at $508K in Q1 2022.
  • 250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Cornerstone National Bank & Trust's 13F filing for Q3 2022, filed 28 Jan 2026.